Clinical Trial Update: Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 dose-escalation study tested everolimus (RAD001) in combination with trastuzumab for HER2-positive metastatic breast cancer; the trial is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (RAD001) (everolimus)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-03-10